75 million Covaxin doses supplied, more by September, says Bharat Biotech’s Suchitra Ella

NEW DELHI: Bharat Biotech on Thursday informed that the Hyderabad- based company has till now supplied 75 million doses of its Covid-19 vaccine Covaxin and more will be supplied this month.

Speaking during the session on Ensuring Affordable, Accessible Health for All at the CII Annual Meeting 2021, Joint Managing Director of Bharat Biotech, Suchitra Ella said, “We have done a supply of 75 million doses of Covaxin and more will be done in August.”

Recently, the Union Health Minister Mansukh Mandaviya announced that Bharat Biotech’s Ankleshwar facility has been given the go-ahead to produce Covaxin doses.

Suchitra Ella said that Covaxin has 65 per cent efficacy against Delta variant of Covid-19.”Our vaccine has 65 per cent efficacy against delta variant. Our second site is at Ankleshwar-based manufacturing plant that will also produce COVID-19 vaccine Covaxin. We have diverted sample batches that will be ready by this month. Samples will go to CDL Kasauli for quality testing,” said Ella.

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic coronavirus and 65.2 per cent protection against the Delta variant, Bharat Biotech had informed recently, while announcing the final analysis of the jab.

Recently, Union Health Minister Mansukh Mandaviya addressing a session on Ensuring Affordable, Accessible Health for All at the CII Annual Meeting 2021 lauded the private sector for working in tandem with the government to meet the shortage of healthcare facilities such as oxygen, injections, medicines etc during the pandemic. Many companies repurposed their facilities to produce masks, PPEs, and ventilators, he said.

At the event, Suchitra Ella also spoke about the company’s efforts to increase the capacity of the vaccine.

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad